Navigation Links
K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
Date:12/12/2012

Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2012 and under the heading "Risk Factors" in our Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 31, 2012. Further, any forward-looking statement speaks only as of the date on which it is made and we are under no obligation to update any of the forward-looking statements after the date of this release. New factors emerge from time to time, and it is not possible for us to predict which factors will arise, when they will arise and/or their effects. In addition, we cannot assess the impact of each factor on our future business or financial condition or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.


'/>"/>
SOURCE K-V Pharmaceutical Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ...
(Date:12/24/2014)... Earlier this year in a June 24 international conference ... Cell Technology Center, LLC ( ASCTC ) focused attention on ... tissue stem cells. His title “Asymmetric Self-Renewal by Distributed ... embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... Continuing Resolution Appropriations Act of 2015, which for the ... funding through the Congressionally Directed Medical Research Programs (CDMRP) ... Association (HA), working in conjunction with its allies on ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... ... States Food and Drug Administration (K083292) of its Habib™ EndoHPB device for the palliation ... ... for marketing by the United States Food and Drug Administration (K083292) of its Habib™ ...
... , , ARLINGTON, Va., July ... today from GPhA President and CEO Kathleen Jaeger on the Senate ... "While we are extremely disappointed that the Committee action ... biogenerics, we will continue to fight in the House to ensure ...
... National Institutes of Health have turned simple baker,s yeast into ... for drugs to treat Parkinson,s disease. In a study ... researchers showed that they can rescue yeast cells from toxic ... the cells to make very small proteins called cyclic peptides. ...
Cached Biology Technology:EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours 2GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients 2Novel drug discovery tool could identify promising new therapies for Parkinson's disease 2Novel drug discovery tool could identify promising new therapies for Parkinson's disease 3Novel drug discovery tool could identify promising new therapies for Parkinson's disease 4
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics company, today ... in genetic ancestry of individuals from across the ... more than four hundred years ago, the United ... peoples from different continents. This study illuminates how American history ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics ... to detect and prevent counterfeit microcircuits from entering into ... performing an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. ... while increasing their reliability throughout the supply chain. The ...
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced ... 2015-2019" report to their offering. ... upcoming in this market is the increasing demand for ... recording of patient data for quick and correct diagnosis ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... of Medicine researchers have discovered how the membrane protein ... this protein becomes desensitized so that one no longer ... an advance online publication by Nature Neuroscience, focused on ... found in many other receptors, including ones involved in ...
... self-replicating, mineralizing agent, has been identified by National Aeronautics ... in kidney stone formation among astronauts. With the potential ... Mars, longer missions, and exposure to the elements of ... , To further comprehend the implications of NB, trials ...
... sclerosis (MS) can be an unpredictable disease. It ... nerve cells and disrupts normal nerve signaling. Patients ... pain, fatigue, and blurred vision—that can appear independently ... appear in no particular order, flare-ups are common ...
Cached Biology News:Gene Signatures Predict Interferon Response For Multiple Sclerosis Patients 2
... transporter 2 (APT2) (Peptide ... PSF2) (Peptide supply factor ... involved in antigen processing ... Antigen: Recombinant ...
... epitope specific for Nabeta2 is ... known proteins.,SPECIES REACTIVITIES: It ... human because the immunogen sequence ... Reactivity with other species has ...
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Biology Products: